Dianthus EVP trades options, sells 26,530 shares
Dianthus Therapeutics EVP and Head of R&D Simrat Randhawa reported option exercises and share sales in common stock.
Rhea-AI Filing Summary
Dianthus Therapeutics EVP and Head of R&D Simrat Randhawa reported option exercises and share sales in common stock. On June 1, 2026, Randhawa exercised stock options for a total of 26,530 shares of common stock at exercise prices between $8.44 and $22.07 per share.
On the same date, Randhawa sold 26,530 shares of common stock in open-market transactions at weighted average prices reported as $89.72, $90.72, and $91.37 per share, with actual trade prices ranging from $89.17 to $91.96. The filing notes these sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on August 14, 2025, indicating the transactions were scheduled in advance.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 26,530 shares ($1.90M approx. pre-tax spread)
Exercise and Sale
11 txns
Insider
Randhawa Simrat
Role
EVP, Head of R&D
Sold
26,530 shs ($2.40M)
Approx. gross sale proceeds
$2.40M
Approx. exercise cost
$500K
Approx. pre-tax spread
$1.90M
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 3,998 | $0.00 | $0.00 |
| Exercise | Stock Option (Right to Buy) | 6,908 | $0.00 | $0.00 |
| Exercise | Stock Option (Right to Buy) | 6,249 | $0.00 | $0.00 |
| Exercise | Stock Option (Right to Buy) | 9,375 | $0.00 | $0.00 |
| Exercise | Common Stock | 3,998 | $8.44 | $34K |
| Exercise | Common Stock | 6,908 | $17.88 | $124K |
| Exercise | Common Stock | 6,249 | $21.77 | $136K |
| Exercise | Common Stock | 9,375 | $22.07 | $207K |
| Sale | Common Stock | 5,428 | $89.72 | $487K |
| Sale | Common Stock | 16,943 | $90.72 | $1.54M |
| Sale | Common Stock | 4,159 | $91.37 | $380K |
Holdings After Transaction:
Stock Option (Right to Buy) — 209,076 contracts (Direct);
Common Stock — 4,000 shares (Direct)
Footnotes (8)
- F1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 14, 2025.
- F2. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $89.17 to $90.16, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- F3. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $90.17 to $91.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- F4. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $91.17 to $91.96, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- F5. The shares of common stock underlying this stock option award vested as to 25% of the shares on April 25, 2023, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
- F6. The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after January 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
- F7. The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after May 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
- F8. The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after January 1, 2025, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
Key Figures
Shares sold: 26,530 shares
Sale prices (weighted averages): $89.72, $90.72, $91.37 per share
Trade price ranges: $89.17–$91.96 per share
+3 more
6 metrics
Shares sold
26,530 shares
Total common shares sold in open-market transactions on June 1, 2026
Sale prices (weighted averages)
$89.72, $90.72, $91.37 per share
Weighted average prices for reported sale blocks
Trade price ranges
$89.17–$91.96 per share
Price ranges across multiple sale transactions
Options exercised
26,530 shares
Total common shares acquired via stock option exercises
Option exercise prices
$8.44, $17.88, $21.77, $22.07 per share
Exercise prices for stock option grants converted to common stock
Rule 10b5-1 plan adoption date
August 14, 2025
Date the pre-arranged trading plan governing these sales was adopted
Key Terms
Rule 10b5-1 trading plan, weighted average price, Stock Option (Right to Buy), stock option award, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 14, 2025."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging..."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
stock option award financial
"The shares of common stock underlying this stock option award vested as to 25% of the shares on April 25, 2023..."
A stock option award is a grant that gives an employee the right to buy a company’s shares at a fixed price for a limited time, often becoming available gradually over a set schedule. Investors care because these awards align workers’ incentives with company performance, can increase employee loyalty, and may create future share dilution and compensation expense that affect earnings per share and shareholder value.
vest in equal monthly installments financial
"The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after January 1, 2024..."
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did Dianthus Therapeutics (DNTH) report for Simrat Randhawa?
Dianthus Therapeutics reported that EVP and Head of R&D Simrat Randhawa exercised options for 26,530 common shares and sold 26,530 shares in open-market transactions on June 1, 2026, according to a Form 4 insider trading disclosure.
What stock options did the Dianthus Therapeutics (DNTH) EVP exercise in this Form 4?
Simrat Randhawa exercised stock options covering 26,530 shares of Dianthus Therapeutics common stock. The reported exercise prices were $8.44, $17.88, $21.77, and $22.07 per share, converting derivative awards into common shares before the related open-market sales.
Was the Dianthus Therapeutics (DNTH) insider sale under a Rule 10b5-1 trading plan?
Yes. The Form 4 footnotes state the transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 14, 2025, meaning the timing and size of the reported sales were pre-arranged rather than decided at the time of trading.
What role does the insider have at Dianthus Therapeutics (DNTH) in this Form 4?
The reporting person, Simrat Randhawa, is identified as Executive Vice President and Head of R&D at Dianthus Therapeutics. The Form 4 shows direct ownership transactions in the company’s common stock and related stock options associated with this executive position.
Did the Dianthus Therapeutics (DNTH) EVP retain any stock options after these exercises?
The Form 4 shows remaining option balances for several grants and a zero balance for one $8.44 strike option after exercising 3,998 shares, indicating that particular award was fully exercised while others continue with remaining shares outstanding.
AI-generated analysis. How Rhea-AI works. Not financial advice.
